Predictors of negotiated prices for new drugs in Germany
| Autor: | Afschin Gandjour, Thomas Hammerschmidt, Charalabos-Markos Dintsios, Sofia Schüßler |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
media_common.quotation_subject
Economics Econometrics and Finance (miscellaneous) Innovative medicines Sample (statistics) Drug Costs Negotiation 03 medical and health sciences 0302 clinical medicine Germany Humans 030212 general & internal medicine Reimbursement health care economics and organizations media_common Original Paper Health economics Actuarial science I18 Negotiating 030503 health policy & services Health Policy AMNOG Regression analysis Arbitration Costs and Cost Analysis Quality of Life Business 0305 other medical science Prediction Pricing Public finance |
| Zdroj: | The European Journal of Health Economics |
| ISSN: | 1618-7601 |
| Popis: | Introduction In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration. The purpose of this study was to identify drivers of negotiated (including arbitrated) prices of new, non-orphan innovative medicines in Germany. Methods The analysis considered all non-orphan drugs that underwent a benefit appraisal between January 2011 and June 2016, and displayed a reimbursement price in the German Drug Directory (Lauer-Taxe®) in November 2017. Negotiated annual treatment costs were analyzed with respect to 11 explanatory variables in regression models. Results The total sample included 106 non-orphan drugs. The analysis showed a significant and positive association of log-transformed negotiated annual treatment cost of new medicines with log-transformed annual treatment cost of its comparator(s), extent of added benefit, and log-transformed size of the target population. Analyzing the effects of specific endpoints instead of the overall added benefit revealed that the single endpoint with the largest impact on price is adverse events (AEs). Surprisingly, an increase in AEs significantly increased the price. Various subgroup and sensitivity analyses demonstrated the robustness of the results. The adjusted R squared for all models was above 80%. Conclusions The analysis was able to confirm that variables whose consideration is mandated by law are, in fact, the key drivers of negotiated prices. Somewhat puzzling, the analysis also found an increase in AEs to move prices significantly upward. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink